XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 82 filers reported holding XENON PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,617,442 | -10.1% | 47,349 | +1.3% | 0.01% | -18.8% |
| Q2 2023 | $1,798,836 | +21.0% | 46,723 | +12.5% | 0.02% | +23.1% |
| Q1 2023 | $1,486,287 | -11.0% | 41,528 | -2.0% | 0.01% | -13.3% |
| Q4 2022 | $1,670,689 | +36.3% | 42,371 | +24.8% | 0.02% | +25.0% |
| Q3 2022 | $1,226,000 | +28.0% | 33,959 | +7.8% | 0.01% | +33.3% |
| Q2 2022 | $958,000 | -48.6% | 31,498 | -47.2% | 0.01% | -57.1% |
| Q4 2021 | $1,865,000 | +142.2% | 59,702 | +18.4% | 0.02% | +200.0% |
| Q3 2021 | $770,000 | -23.4% | 50,415 | -6.6% | 0.01% | -22.2% |
| Q2 2021 | $1,005,000 | -11.4% | 53,959 | -14.8% | 0.01% | -18.2% |
| Q1 2021 | $1,134,000 | +16.5% | 63,331 | +0.1% | 0.01% | 0.0% |
| Q4 2020 | $973,000 | +97.0% | 63,254 | +41.7% | 0.01% | +57.1% |
| Q3 2020 | $494,000 | -17.4% | 44,624 | -6.5% | 0.01% | -12.5% |
| Q2 2020 | $598,000 | +29.2% | 47,704 | -7.1% | 0.01% | +100.0% |
| Q3 2019 | $463,000 | -12.8% | 51,356 | -4.7% | 0.00% | 0.0% |
| Q2 2019 | $531,000 | -14.2% | 53,888 | -11.6% | 0.00% | 0.0% |
| Q1 2019 | $619,000 | +69.6% | 60,964 | +5.5% | 0.00% | +33.3% |
| Q4 2018 | $365,000 | – | 57,796 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ghost Tree Capital, LLC | 850,000 | $15,215,000 | 3.58% |
| ACUTA CAPITAL PARTNERS, LLC | 412,500 | $7,384,000 | 2.66% |
| BVF INC/IL | 3,481,778 | $62,324,000 | 2.34% |
| Soleus Capital Management, L.P. | 708,117 | $12,675,000 | 2.28% |
| COMMODORE CAPITAL LP | 301,392 | $5,395,000 | 2.15% |
| DAFNA Capital Management LLC | 406,535 | $7,277,000 | 1.73% |
| Parkman Healthcare Partners LLC | 374,395 | $6,702,000 | 1.56% |
| Avoro Capital Advisors LLC | 3,650,000 | $65,335,000 | 1.13% |
| KNOTT DAVID M | 144,101 | $2,579,000 | 1.10% |
| Orbimed Advisors | 2,497,917 | $44,713,000 | 0.42% |